Clinical Trials
15 trialsNCT05272384 2026-05-13
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03038672 2026-05-12
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04205409 2026-05-12
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Phase 2 Completed
NCT05255601 2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03749018 2026-02-06
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03884998 2025-12-30
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03015896 2025-09-29
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03843294 2025-07-03
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Children's National Research Institute
Phase 1 Active not recruiting
NCT03311958 2025-04-06
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Fox Chase Cancer Center
Phase EARLY_PHASE1 Completed
NCT03484819 2025-03-03
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03892044 2024-05-02
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT03305445 2023-02-15
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT03259529 2021-06-07
BeGeRN
St. Petersburg State Pavlov Medical University
Phase 1/2 Completed
NCT03558750 2019-04-25
Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated